Fig. 2: Vaccine effectiveness estimates with 95% confidence intervals against hospitalisations using ECDS by age group and manufacturer (all symptomatic controls, Omicron only). | Nature Communications

Fig. 2: Vaccine effectiveness estimates with 95% confidence intervals against hospitalisations using ECDS by age group and manufacturer (all symptomatic controls, Omicron only).

From: Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study

Fig. 2

a 18–64: Two doses of ChAdOx1-S with a BNT162b2 or mRNA-1273 third dose, b 18–64: two doses of BNT162b2 with a BNT162b2 or mRNA-1273 third dose, c 65 and older: two doses of ChAdOx1-S with a BNT162b2 or mRNA-1273 third dose, d 65 and older: two doses of BNT162b2 with a BNT162b2 or mRNA-1273 third dose, Vaccine effectiveness estimates are adjusted using sex, index of multiple deprivation (quintile), ethnic group, care home residence status (for age 65+), geographic region (NHS region), period (calendar week of the test), health and social care worker status (for age <65), clinical risk group status (for age <65), clinically extremely vulnerable, severely immunosuppressed, and previously tested positive.

Back to article page